Evidence map›Paper›PMID 41561093›Full record

ArticleFrontiers in cellular and infection microbiology2025

Synergistic effects of dioscin and amphotericin B against

Xin Liu, Fei Xu, Yu Zhang, Lili Zhong, Longfei Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xin LiuEye Center, The Second Hospital of Jilin University, Changchun, China.
Fei XuDepartment of Acupuncture and Moxibustion, The Second Hospital of Jilin University, Changchun, China.
Yu ZhangDepartment of Clinical Laboratory, The Second Hospital of Jilin University, Changchun, China.
Lili ZhongJilin Provincial Key Laboratory on Molecular and Chemical Genetics, The Second Hospital of Jilin University, Changchun, China.
Longfei YangJilin Provincial Key Laboratory on Molecular and Chemical Genetics, The Second Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emerging antifungal resistance exacts deteriorating effects on the availability of drugs for treating fungal infections, calling for novel therapies. Although amphotericin B (AmB) is clinically effective and rarely causes resistance, its severe side effects warrant further reduction. Enhancing or potentiating AmB efficacy with other agents to lower the dose of AmB is appealing to reduce AmB toxicity. Dioscin, a steroidal saponin from the

Indexed as

Amphotericin BAntifungal AgentsCandida albicansDiosgeninDrug SynergismBiofilmsCandidaCell MembraneHumansMicrobial Sensitivity TestsSaponinsAmphotericin BAntifungal AgentsdioscinDiosgeninSaponinsamphotericin B (AmB)antifungalCandida albicansdioscinsynergyvirulence factors

Identifiers

PMID41561093
PMCPMC12813175

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.